Immunohistochemically, STZ treatment reduced NeuN level in dentate gyrus (DG, 90%, p = .031) and Cornu Ammonis areas 1 (CA1, 89%, p = .015) and 3 (CA3, 91%, p = .023) of the hippocampus of 3 × Tg‐AD mice (STZ group), whereas LM‐031 treatment could reduce this decrease to 97% (DG, p = .045), 96% (CA1, p = .148), and 95% (CA3, p = .053) (STZ/LM‐031 group) compared to the normoglycemic control (– STZ group, 100%) (Figure S7c). The gene discussed is RBFOX3; the disease is Alzheimer disease.